2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

908. Outcomes Research: Myeloid Malignancies: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Vaccines, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, APL, MDS, MPN, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6341 Myelodysplastic syndrome and sodium-glucose cotransporter-2 inhibitor exposure: A real-world cohort study

Jordan Nunnelee, MD, Yoshito Nishimura, M.D., PhD, MPH2, Richard C. Godby, MD3
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States

Introduction

Myelodysplastic syndrome (MDS) is often complicated by transfusion-dependent anemia, requiring significant healthcare utilization. In addition to packed red blood cell (PRBC) transfusions, patients may require erythropoiesis stimulating agents (ESAs) and/or luspatercept for treatment of anemia. Symptoms of anemia and frequent supportive treatments are often a significant source of poor quality of life in this patient population. Sodium–glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated pleiotropic anti-inflammatory, immunomodulatory, and other organ-protective effects beyond glycemic control. Moreover, SGLT2i increase endogenous erythropoietin (EPO) synthesis and hemoglobin levels without increased risk of myocardial infarction or venous thromboembolism. However, the potential impact of SGLT2i on survival and anemia-specific factors in patients with MDS has not been elucidated.

Methods

We conducted a retrospective cohort analysis using an institutional de-identified data exploration tool, identifying adult patients diagnosed with MDS (ICD-10 code D46.9)  with a concurrent diagnosis of anemia from March 2013 (first approval of SGLT2i) to February 2026. Patients with a diagnosis of acute myeloid leukemia were excluded. Patients were then stratified based on exposure to SGLT2i. The prespecified primary endpoint was PRBC transfusion rate, and the secondary endpoint was five-year overall survival (OS). Propensity-score matching (PSM) was performed for the following covariates: age at diagnosis, race, ethnicity, sex, and diagnoses of type 2 diabetes mellitus (T2DM), congestive heart failure (CHF), and chronic kidney disease (CKD). Mutually exclusive 1:1 matching was used with a caliper of 0.2. Survival was estimated by the Kaplan–Meier method and compared using the log-rank test. Hazard ratios (HRs) were derived from Cox proportional-hazards models. Categorical outcomes were compared using the χ² test. A two-sided P value less than .05 was considered statistically significant.

Results

267 (4.9%) patients with MDS were exposed to SGLT2i and 5,2480 (95.1%) were not exposed. There were 263 patients in each group after PSM. Baseline demographics in the PSM groups were comparable and diagnoses (T2DM, CHF, and CKD) were matched without significant differences between groups. The median age in the SGLT2i exposed group vs. unexposed was 74.0 years (interquartile range (IQR) 67.0-79.3) vs. 73.2 years (IQR 67.0-80.0) at first diagnosis match. Patients in the SGLT2i exposed and unexposed groups were predominantly male (73.8 % vs. 73.0%, P = .84) and white (90.9% vs. 92.8%, P = .43).

Patients exposed to SGLT2i had a significantly lower chance of receiving PRBC transfusion (19.4% vs. 29.7%, P = .006). Both one-year and five-year OS were significantly improved among patients exposed to SGLT2i compared to those not exposed (85.3% vs. 73.7%, HR 0.53, 95% CI: 0.35-0.79, P = .002; 62.0% vs. 38.6%, HR 0.50, 95% CI: 0.37-0.67, P < .001, respectively). There was no difference in ESA use (9.9% vs. 11.8%, P = .48).

Conclusions

In this large real-world cohort of patients diagnosed with MDS, SGLT2i exposure was associated with improved short- and long-term survivals, and lower PRBC exposure. There was a similar rate of ESA use. These findings suggest anemia-specific benefits of SGLT2i therapy that mitigate transfusion burden in these patients with MDS. While causality cannot be inferred from this retrospective analysis, further investigations and prospective evaluations are warranted to determine the potential benefits of SGLT2i therapy as an anemia-targeted adjunct to spare patients of transfusion dependence, and to elucidate underlying mechanisms leading to the survival benefits seen in this study.

Jordan Nunnelee, MD: No relevant conflicts of interest to declare.